Joyce University Expands Nursing Education to Michigan Students
Over the last three years, Joyce University has steadily expanded beyond Utah, now serving students in 14 states, including its latest additions in 2025: Michigan and Kentucky. This growth reflects the university's commitment to providing flexible, career-focused educational pathways to meet the increasing demands for skilled nurses throughout Michigan.
With this expansion, students in Michigan can access a range of pre-licensure programs, such as the 20-month Associate of Science in Nursing (ASN), the 3-year Bachelor of Science in Nursing (BSN), and the accelerated Bachelor of Science in Nursing (aBSN). Joyce University offers two post-licensure programs for those looking to further their nursing careers: the 4-semester online RN to BSN program and the 3-semester online MSN in Leadership program.
Students benefit from a hybrid approach, attending online lectures while gaining hands-on experience at the Joyce Johnson Center of Simulation in Draper, Utah. To minimize travel and foster local connections, clinical experiences take place in each student's state of residence.
Enrollment for Michigan students is now open, with the next cohort starting in the Fall Semester on September 2nd.
For more information about Joyce University programs or employment opportunities, visit joyce.edu.
ABOUT JOYCE UNIVERSITY
Founded in 1979, Joyce University of Nursing and Health Sciences ' mission is to prepare students to serve as competent professionals, to advance their careers, and to pursue lifelong learning. Located in Draper, Utah, Joyce University is proud to have helped thousands of students across the US graduate and launch lasting healthcare careers. With a recent expansion of its pre-licensure programs to select regional locations, including Arizona, Colorado, Idaho, Kentucky, Michigan, Missouri, Nevada, New Mexico, Ohio, Oregon, South Carolina, and Wisconsin. Joyce University's expansion enables aspiring nurses in these regions to access the same high-quality education and opportunities that have defined the institution for decades. Join them as they continue to shape the future of healthcare, one student at a time.
Joyce University is institutionally accredited by the Northwest Commission on Colleges and Universities (NWCCU) and programmatically accredited by the Accreditation Commission for Education in Nursing (ACEN) for the Associate of Science in Nursing degree program and by the Commission on Collegiate Nursing Education (CCNE) for the Bachelor of Science in Nursing and Master of Science in Nursing degree programs.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
2 hours ago
- Business Wire
CORRECTING and REPLACING Polio Vaccination Campaign Planned in Afghanistan with PharmaJet
GOLDEN, Colo.--(BUSINESS WIRE)--Please replace the release dated Aug. 19, 2025 with the following corrected version due to multiple revisions - removing mentions of WHO and UNICEF and all operational details which are subject to national authorities and partners agreement. The updated release reads: Polio Vaccination Campaign Planned in Afghanistan with PharmaJet ® Tropis ® ID Delivery System PharmaJet has been awarded a tender to support the first large-scale implementation of intradermal (ID) polio immunization in Afghanistan. PharmaJet's award builds on the successful implementation of Tropis for ID delivery in polio vaccination campaigns in Pakistan, Nigeria, and Somalia. The use of Tropis ID in polio vaccination campaigns has improved vaccine coverage, decreased immunization program costs, and increased acceptability. PharmaJet ®, a company that strives to improve the performance and outcomes of injectables with its enabling needle-free injection technology, today announced that the WHO prequalified Tropis ID delivery system will be used to support a polio eradication campaign in Afghanistan. Poliovirus has been eliminated in most parts of the world due to widespread vaccination campaigns, but it continues to circulate in Afghanistan and Pakistan. In 2024, wild poliovirus type 1 (WPV1) transmission rose significantly in Afghanistan. The use of Tropis ID enables site-to-site immunization, a strategy where vaccination services are offered at multiple, convenient locations. Including Tropis ID fractional doses of inactivated polio vaccine (fIPV) in this immunization program supports Afghanistan's polio eradication goals to eliminate persistent virus lineages, prevent new WPV1 cases, and prevent local transmission. 'We are pleased to be supporting Afghanistan in their continued efforts to eradicate polio,' said Paul LaBarre, Senior Vice President Global Business Development, PharmaJet. 'We aim to achieve high impact in the fight against poliovirus, including increased coverage, decreased costs, and high acceptability 1 previously seen with Tropis ID delivered fIPV in Pakistan, 1 Somalia, 2 and Nigeria 3.' Refer to Instructions for Use to ensure safe injections and to review risks. About PharmaJet The PharmaJet mission is to improve the performance and outcomes of injectables with our enabling technology that better activates the immune system. We are committed to helping our partners realize their research and commercialization goals while making an impact on public health. PharmaJet Precision Delivery Systems™ can improve vaccine effectiveness, allow for a preferred patient and caregiver experience, and offer a proven path to commercialization. They are also safe, fast, and easy-to-use. The Stratis ® System has U.S. FDA 510(k) marketing clearance, CE Mark, and WHO PQS certification to deliver medications and vaccines either intramuscularly or subcutaneously. The Tropis ® System has CE Mark and WHO PQS certification for intradermal injections. They are both commercially available for global immunization programs. For more information or if you are interested in partnering with PharmaJet visit or contact PharmaJet here. Follow us on LinkedIn.
Business Wire
2 hours ago
- Business Wire
New Survey: College Students Feel Coerced Into Participating in Animal Experiments Despite Objections; 83% Oppose Such Exercises
WASHINGTON--(BUSINESS WIRE)--Eighty-three percent of U.S. college students believe that animals should not be used in classroom teaching laboratories if the animals are killed afterward and if other methods can teach the same material without using animals, according to a new OpinionWorks survey. Among those majoring in the sciences, 90% believe animals should not be used. The survey, which was conducted online among 1,043 U.S. undergraduate college students from Aug. 8 to 10, 2025, also posed the hypothetical scenario in which such an animal laboratory was offered as an optional experience, along with a nonanimal alternative. In that case, although most students did not want to participate, 20% stated they would do so anyway to avoid problems, and another 24% stated that they would be nervous asking for the alternative activity. The survey also found an overwhelming majority of students, 79%, expressed concern about the welfare of animals. 'The vast majority of college students don't want to participate in deadly animal experiments in the classroom but feel subtly coerced because they are fearful of the consequences of not taking part,' says Neal Barnard, MD, president of the Physicians Committee for Responsible Medicine. 'Colleges with old-fashioned animal labs put students in an awful position that many interpret as a choice between killing or flunking.' The survey results arrive amid an ongoing lawsuit against fatal animal experiments at Macalester College in Saint Paul, Minn., where students will begin arriving for the new school year on Aug. 25. In psychology courses at Macalester, live animals are deprived of water for prolonged periods, then placed in 'Skinner boxes,' where they have to work for water. Some experiments involve drugging animals and placing them in mazes. All are killed at the conclusion of the experiments. Harvard, Yale, Stanford, Princeton, and other leading universities stopped the Macalester-style fatal experiments long ago. The new survey found that 76% of college students do not approve of the use of live animals in psychology classes when the animals are killed afterward and when there are alternative teaching methods. Macalester's website says that its 'animal welfare standards and ethical principles are applied at the highest possible level in any animal use or research conducted at or in association with the college' and that it follows the federal Animal Welfare Act, which incorporates ethical principles called the Three Rs—for the replacement, reduction, and refinement of animal use in research. A lawsuit against Macalester, brought by alumnus Dr. Barnard on June 3, calls on the college to stop needlessly killing animals in psychology classes' 'show and tell' exercises, citing the college's posted ethics commitment. The psychology department has killed thousands of animals for more than 50 years. The college stated in its motion to dismiss, which Dr. Barnard responded to in court papers, that its own ethics statements are mere 'generic phrases'—known legally as 'puffery.' The college wrote, 'These statements are, at most, 'vague or highly subjective' statements of superiority—not representations of material fact,' drawing comparisons with statements used to sell dog food or breakfast cereal. 'Given that animals' lives are at stake, Macalester's brazen statement that it did not really mean its ethics policy is an affront to students, donors, the faculty, and the public,' Dr. Barnard said. The lawsuit seeks, among other actions, an order compelling Macalester 'to cease its use of animal laboratories in psychology instruction and in all other areas for which nonanimal methods are available.' To speak with Dr. Barnard, please contact Michael Keevican at 202-527-7367 or mkeevican@ Founded in 1985, the Physicians Committee for Responsible Medicine is a nonprofit organization that promotes preventive medicine, conducts clinical research, and encourages higher standards for ethics and effectiveness in education and research.
Business Wire
4 hours ago
- Business Wire
Develop Health Raises $14.3M to Automate Prior Authorization and Medication Access Using GenAI
SAN FRANCISCO--(BUSINESS WIRE)-- Develop Health, an EHR-integrated benefits‑verification and prior‑authorization platform, today announced a $14.3 million Series A led by Wing Venture Capital, with participation from Afore Capital, J Ventures, and South Park Commons. The round brings the company's total funding to $17.6 million. Built with over a dozen purpose-built large language model pipelines, Develop Health is the first medication access platform fully architected around GenAI. Its EHR-integrated platform plugs into virtual care workflows to verify insurance coverage in real time, generate and submit the correct prior authorization package, follow up and track status continuously, and return structured data back into the provider's system, all without manual effort from care teams. Founded by Mel van Londen and Benjamin Easton, Develop Health is tackling a growing bottleneck in healthcare: the administrative complexity that delays access to necessary medications. Before Develop Health, the founders held roles at provider-facing healthcare startups Canvas Medical and Rupa Health, where they saw how poor communication and data fidelity between providers and payers led to delayed treatment, lost revenue, and worse outcomes for patients. 'We believe providers should be able to make care decisions with full visibility into a patient's plan, because a prescription that isn't affordable or accessible is no prescription at all,' said Mel van Londen, co-founder and CEO of Develop Health. 'We're building healthcare's agentic clearinghouse, starting with medication access and designing infrastructure that meets both payers and providers where they are.' The new funding will fuel Develop Health's expansion beyond its core work helping digital health companies navigate the pharmacy benefit space—spanning GLP-1s and treatments across addiction, neurology, dermatology, and psychiatry—into the medical benefit market. The company will also deepen its integrations with both EHRs and PBMs, streamlining and scaling the link between prescribing and coverage, and extend its reach into traditional providers outside of digital health. 'Develop Health is solving one of the most frustrating pain points in healthcare – getting patients the medications they need without weeks of paperwork and endless back-and-forth,' said Sara Choi, Partner at Wing Venture Capital. 'They've built a system that puts GenAI to work in one of the industry's most critical, overlooked workflows. Develop Health is positioned to become essential infrastructure for any provider dealing with medication access complexity. ' Today, Develop Health helps providers reduce churn, set clearer patient expectations, and streamline access to care. The platform reduces form completion time by over 80% and increases approval rates, improving both provider efficiency and patient experience. In just three months, the company has grown significantly and is on track to helping over 1 million patients access their medications by the end of this year. That traction has been driven by Develop Health's exceptional team of engineers, including Jack Collins, Juan de Urtubey, and Zygimantas Koncius, whose technical excellence has made the platform possible. About Develop Health Develop Health's mission is to empower providers by eliminating the friction of prior authorization and improving visibility into plan benefits—freeing up capacity to deliver truly high-quality patient care. At its core, Develop Health is healthcare's agentic clearinghouse, beginning with medication access. Today, the platform supports hundreds of thousands of patients each month in getting the treatments they need—while reducing administrative work related to medication access by 83%. Learn more at
